136 related articles for article (PubMed ID: 19725034)
1. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
[TBL] [Abstract][Full Text] [Related]
2. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
[TBL] [Abstract][Full Text] [Related]
3. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
5. Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer.
Lo SH; Lo TB
Cancer Res; 2002 Aug; 62(15):4217-21. PubMed ID: 12154022
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.
Yin B; Zhang M; Zeng Y; Li Y; Zhang C; Getzenberg RH; Song Y
Int J Oncol; 2016 Apr; 48(4):1730-6. PubMed ID: 26892177
[TBL] [Abstract][Full Text] [Related]
8. ΔNp63α Transcriptionally Regulates the Expression of CTEN That Is Associated with Prostate Cell Adhesion.
Yang K; Wu WM; Chen YC; Lo SH; Liao YC
PLoS One; 2016; 11(1):e0147542. PubMed ID: 26784942
[TBL] [Abstract][Full Text] [Related]
9. C-terminal tensin-like protein mediates invasion of human lung cancer cells and is regulated by signal transducer and activator of transcription 3.
Bennett DT; Reece TB; Foley LS; Sjoberg A; Meng X; Fullerton DA; Weyant MJ
J Thorac Cardiovasc Surg; 2015 Jan; 149(1):369-75. PubMed ID: 25439778
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.
Machioka K; Izumi K; Kadono Y; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Keller ET; Zhang J; Mizokami A
Oncotarget; 2018 Mar; 9(22):16185-16196. PubMed ID: 29662635
[TBL] [Abstract][Full Text] [Related]
11. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
12. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.
Katz M; Amit I; Citri A; Shay T; Carvalho S; Lavi S; Milanezi F; Lyass L; Amariglio N; Jacob-Hirsch J; Ben-Chetrit N; Tarcic G; Lindzen M; Avraham R; Liao YC; Trusk P; Lyass A; Rechavi G; Spector NL; Lo SH; Schmitt F; Bacus SS; Yarden Y
Nat Cell Biol; 2007 Aug; 9(8):961-9. PubMed ID: 17643115
[TBL] [Abstract][Full Text] [Related]
13. Multiple pathways regulate Cten in colorectal cancer without a Tensin switch.
Thorpe H; Akhlaq M; Jackson D; Al Ghamdi S; Storr S; Martin S; Ilyas M
Int J Exp Pathol; 2015 Dec; 96(6):362-9. PubMed ID: 26852686
[TBL] [Abstract][Full Text] [Related]
14. C-terminal tensin-like gene functions as an oncogene and promotes cell motility in pancreatic cancer.
Al-Ghamdi S; Cachat J; Albasri A; Ahmed M; Jackson D; Zaitoun A; Guppy N; Otto WR; Alison MR; Kindle KB; Ilyas M
Pancreas; 2013 Jan; 42(1):135-40. PubMed ID: 22750970
[TBL] [Abstract][Full Text] [Related]
15. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract][Full Text] [Related]
16. C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer.
Albasri A; Seth R; Jackson D; Benhasouna A; Crook S; Nateri AS; Chapman R; Ilyas M
J Pathol; 2009 May; 218(1):57-65. PubMed ID: 19214987
[TBL] [Abstract][Full Text] [Related]
17. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
Sun NK; Huang SL; Lu HP; Chang TC; Chao CC
Oncotarget; 2015 Sep; 6(29):27065-82. PubMed ID: 26318424
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
19. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
Ohigashi T; Mizuno R; Nakashima J; Marumo K; Murai M
Prostate; 2005 Jan; 62(1):61-8. PubMed ID: 15389810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
